|

Purified regulatory T-cells (Treg) plus CD34+ HSPC Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Stanford University1

Indications

  • Myeloproliferative Disorders1
  • Chronic Myelogenous Leukemia1
  • Advanced Hematologic Malignancies1
  • Allogeneic Hematopoietic Cell Transplantation (HCT)1
  • Acute Leukemia1

Stanford, California1 trial

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Stanford University

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.